Brief: Almirall And Paratek Enter Into License Agreement For Seysara In China
24/02/2020 06:59
Feb 24 (Reuters) - Almirall SA ALM.MC :
* SAYS ALMIRALL AND PARATEK ENTER INTO A LICENSE AGREEMENT
FOR
SEYSARA IN CHINA
* COMPANY TO BE RESPONSIBLE FOR DEVELOPMENT, REGISTRATION
AND
COMMERCIALIZATION OF PRODUCT IN CHINA IN EXCHANGE FOR ROYALTIES
CALCULATED AS PERCENTAGE OF NET SALES ONCE PRODUCT IS LAUNCHED
* TO PROVE EFFICIENCY AND SAFETY OF MEDICINE IN CHINA,
ALMIRALL TO
CONDUCT PHASE III AND PK STUDY AMONG CHINESE POPULATION STARTING
IN 2020
Source text for Eikon: ID:nNDLb1cy7N
Further company coverage: ALM.MC
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Paratek Pharmaceuticals
See all newsNovo Holdings closes $462 mln acquisition of Paratek Pharmaceuticals
Brief: Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Responds to Demand Letters From 11 Stockholders Alleging 'Misleading', Incomplete Statements In Proxy Statement Filed On June 30
Brief: Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue Of $40.0 Million